Vanda Pharmaceuticals Inc. (VNDA)

Vanda Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	125.16	135.82	135.03	52.07	61.03	45.07
Short-Term Investments	268.98	252.44	331.83	380.74	306.71	267.06
Cash & Cash Equivalents	394.14	388.26	466.86	432.81	367.74	312.13
Cash Growth	-21.41%	-16.83%	7.87%	17.70%	17.82%	21.28%
Receivables	36.71	34.16	33.51	32.47	30.04	26.37
Inventory	11.02	11.34	12.57	9.17	7.92	4.99
Other Current Assets	-2.45	-0.82	6.35	3.85	3.45	10.65
Total Current Assets	439.43	432.95	519.29	478.3	409.15	354.14
Property, Plant & Equipment	9.05	9.14	10.97	12.39	14.6	15.04
Goodwill and Intangibles	119.35	121.37	18.57	20.08	21.56	23.04
Other Long-Term Assets	84.86	84.99	85.42	83.03	88.16	91.53
Total Long-Term Assets	213.26	215.49	114.96	115.49	124.31	129.61
Total Assets	652.68	648.44	634.25	593.79	533.46	483.75
Accounts Payable	37.77	38.46	45.55	34.44	31.51	27.59
Other Current Liabilities	55.57	49.24	45.89	39.98	34.43	31.92
Total Current Liabilities	93.34	87.7	91.44	74.42	65.94	59.51
Long-Term Debt	6.51	7.01	8.81	10.06	11.5	12.46
Other Long-Term Liabilities	8.83	8.83	6.8	4.39	2.76	0.84
Total Long-Term Liabilities	15.35	15.83	15.61	14.45	14.25	13.3
Total Liabilities	108.69	103.53	107.05	88.86	80.19	72.8
Total Debt	6.51	7.01	8.81	10.06	11.5	12.46
Debt Growth	-22.33%	-20.50%	-12.35%	-12.54%	-7.69%	-
Retained Earnings	-159.54	-155.39	-157.9	-164.18	-197.33	-220.67
Comprehensive Income	-0.38	-0.03	-1.19	-0.18	0.24	0.25
Shareholders' Equity	544	544.91	527.2	504.93	453.27	410.95
Net Cash / Debt	387.63	381.26	458.05	422.76	356.24	299.67
Net Cash / Debt Growth	-21.39%	-16.76%	8.35%	18.67%	18.88%	16.44%
Net Cash Per Share	6.71	6.62	8.04	7.43	6.45	5.46
Working Capital	346.08	345.25	427.86	403.88	343.21	294.63
Book Value Per Share	9.42	9.50	9.34	9.09	8.33	7.73

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).